MX2022011278A - Metodo para el tratamiento de afecciones asociadas a covid-19. - Google Patents
Metodo para el tratamiento de afecciones asociadas a covid-19.Info
- Publication number
- MX2022011278A MX2022011278A MX2022011278A MX2022011278A MX2022011278A MX 2022011278 A MX2022011278 A MX 2022011278A MX 2022011278 A MX2022011278 A MX 2022011278A MX 2022011278 A MX2022011278 A MX 2022011278A MX 2022011278 A MX2022011278 A MX 2022011278A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- fostamatinib
- pharmaceutically acceptable
- acceptable salt
- active component
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062988876P | 2020-03-12 | 2020-03-12 | |
| US202063038570P | 2020-06-12 | 2020-06-12 | |
| PCT/US2021/021951 WO2021183790A1 (en) | 2020-03-12 | 2021-03-11 | Method for treatment of covid-19-associated conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011278A true MX2022011278A (es) | 2022-12-15 |
Family
ID=77665493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011278A MX2022011278A (es) | 2020-03-12 | 2021-03-11 | Metodo para el tratamiento de afecciones asociadas a covid-19. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12263180B2 (enExample) |
| EP (1) | EP4117728A4 (enExample) |
| JP (1) | JP2023518356A (enExample) |
| KR (1) | KR20220152293A (enExample) |
| CN (1) | CN115768474A (enExample) |
| AU (1) | AU2021234316A1 (enExample) |
| BR (1) | BR112022018235A2 (enExample) |
| CA (1) | CA3175089A1 (enExample) |
| IL (1) | IL296352A (enExample) |
| JO (1) | JOP20220218A1 (enExample) |
| MX (1) | MX2022011278A (enExample) |
| PE (1) | PE20230996A1 (enExample) |
| PH (1) | PH12022552539A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023194840A1 (en) | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Substituted tricyclic compounds and their use in covid-19 |
| CN116440117A (zh) * | 2023-06-14 | 2023-07-18 | 四川省医学科学院·四川省人民医院 | 甲磺酸萘莫司他在制备治疗肾损伤或肾功能不全药物中的应用 |
| CN116650507A (zh) * | 2023-06-28 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 福它替尼在制备治疗放射性肺纤维化药物中的应用 |
| CN118649237A (zh) * | 2024-06-13 | 2024-09-17 | 高维医药(杭州)有限公司 | S蛋白或p4hb蛋白作为靶点在制备预防或治疗新冠感染相关性凝血病变的药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| EP2078026B1 (en) | 2006-11-21 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| UA102825C2 (ru) | 2007-11-07 | 2013-08-27 | Райджел Фармасьютикалз, Инк. | Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду |
| WO2015116729A2 (en) | 2014-01-28 | 2015-08-06 | Emergent Product Development Seattle, Llc | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders |
| WO2016033416A1 (en) * | 2014-08-29 | 2016-03-03 | Board Of Regents, University Of Texas System | Bromodomain inhibitors for treating disease |
| GB202005890D0 (en) * | 2020-04-22 | 2020-06-03 | Aivivo Ltd | New uses |
-
2021
- 2021-03-11 EP EP21768322.6A patent/EP4117728A4/en active Pending
- 2021-03-11 KR KR1020227035071A patent/KR20220152293A/ko active Pending
- 2021-03-11 JP JP2022554956A patent/JP2023518356A/ja active Pending
- 2021-03-11 PH PH1/2022/552539A patent/PH12022552539A1/en unknown
- 2021-03-11 CA CA3175089A patent/CA3175089A1/en active Pending
- 2021-03-11 BR BR112022018235A patent/BR112022018235A2/pt unknown
- 2021-03-11 PE PE2022001945A patent/PE20230996A1/es unknown
- 2021-03-11 AU AU2021234316A patent/AU2021234316A1/en active Pending
- 2021-03-11 JO JOP/2022/0218A patent/JOP20220218A1/ar unknown
- 2021-03-11 MX MX2022011278A patent/MX2022011278A/es unknown
- 2021-03-11 IL IL296352A patent/IL296352A/en unknown
- 2021-03-11 CN CN202180034971.6A patent/CN115768474A/zh active Pending
- 2021-05-18 US US17/323,901 patent/US12263180B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022018235A2 (pt) | 2022-12-20 |
| PH12022552539A1 (en) | 2024-01-22 |
| CN115768474A (zh) | 2023-03-07 |
| KR20220152293A (ko) | 2022-11-15 |
| JP2023518356A (ja) | 2023-05-01 |
| EP4117728A1 (en) | 2023-01-18 |
| EP4117728A4 (en) | 2024-04-17 |
| US20210283152A1 (en) | 2021-09-16 |
| PE20230996A1 (es) | 2023-06-26 |
| US12263180B2 (en) | 2025-04-01 |
| AU2021234316A1 (en) | 2022-10-13 |
| CA3175089A1 (en) | 2021-09-16 |
| IL296352A (en) | 2022-11-01 |
| JOP20220218A1 (ar) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552539A1 (en) | Method for treatment of covid-19-associated conditions | |
| ECSP22077573A (es) | Método para el tratamiento de afecciones asociadas a covid-19 | |
| MX2022011804A (es) | Uso de agentes para el tratamiento de condiciones respiratorias. | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| MX391565B (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| MX2022012576A (es) | Inhibidores de axl para terapia antiviral. | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| WO2020101790A3 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
| MX2022014586A (es) | Métodos y composiciones para tratar la fuga vascular. | |
| MX2025000142A (es) | Tratamiento con ciclobenzaprina para las secuelas postagudas de la infección por (sars)-cov-2 (pasc) | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| EP4374918A3 (en) | Methods of treating fabry patients having renal impairment | |
| EP4491231A3 (en) | Regimen for treating a neisseria gonorrhoeae infection with gepotidacin | |
| Chaudhry et al. | Prevention of venous thromboembolism in patients with hemorrhagic stroke |